Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Recall of Single Lot of Furosemide Tablets, 40 mg
Sandoz, Inc has voluntarily recalled a single lot of Furosemide Tablets, 40 mg, in bottles labeled with the NDC number 0781-1966-10. Furosemide tablets are primarily used for the treatment of high blood pressure and for the treatment of swelling associated with heart failure, liver failure and kidney disease. The single lot number 180974 is being recalled because the tablets may be the wrong size and strength. For more information, please visit: http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm164181.htm
Learn More

FDA Update on Ongoing Safety Review of Cefepime (Maxipime)
The FDA has finished its evaluation of a possible increased risk of death with cefepime (Maxipime). The safety review of cefepime was first announced in November 2007 and since then the FDA has reviewed data from published studies and additional data submitted by Bristol Meyers Squibb, the manufacturer of cefepime (Maxipime). The FDA has determined that the data do not indicate a higher rate of death in cefepime-treated patients. Cefepime, an antibiotic that is administered by infusion into the vein, remains an appropriate therapy for its approved indications which include the treatment of pneumonia, urinary tract infections, skin infections, and abdominal infections. For more information, please visit: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm167427.htm
Learn More

Receive Safety Alerts & Recalls by email or text message.

Register

Date Published Title Drug Source
2009-06-17 Recall of Single Lot of Furosemide Tablets, 40 mg Furosemide FDA
2009-06-17 FDA Update on Ongoing Safety Review of Cefepime (Maxipime) Cefepime FDA
2009-06-16 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children FDA
2009-06-16 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Methylphenidate FDA
2009-06-16 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Amphetamine Salts FDA
2009-06-16 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Cylert FDA
2009-06-16 Warnings on Three Zicam Intranasal Zinc Products Zicam FDA
2009-06-16 Warnings on Three Zicam Intranasal Zinc Products Zinc FDA
2009-06-15 Select Lots of Levemir Insulin (Insulin Detemir [rDNA origin] Injection) Reported Stolen Insulin Detemir FDA
2009-06-15 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Dexmethylphenidate FDA
2009-06-15 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Dextroamphetamine FDA
2009-06-15 Ongoing FDA Safety Review of Stimulant Mediations Used to Treat ADHD in Children Lisdexamfetamine FDA
2009-06-12 Updated Safety Information from FDA Safety Review Montelukast FDA
2009-06-12 Updated Safety Information from FDA Safety Review Zafirlukast FDA
2009-06-12 Updated Safety Information from FDA Safety Review Zileuton FDA
2009-06-11 New Safety Information About the Use of Sirolimus (Rapamune) in LIVER Transplant Patients Sirolimus FDA
2009-06-08 Thiazolidinediones Associated with Increased Risk of Fractures Pioglitazone MediGuard CRT
2009-06-08 Thiazolidinediones Associated with Increased Risk of Fractures Rosiglitazone MediGuard CRT
2009-06-08 Thiazolidinediones Associated with Increased Risk of Fractures Metformin with Rosiglitazone MediGuard CRT
2009-06-08 Thiazolidinediones Associated with Increased Risk of Fractures Pioglitazone and Metformin MediGuard CRT